Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL). J of Skin 2020, 4 (5), s49. https://doi.org/10.25251/skin.4.supp.48.